Results 131 to 140 of about 3,046 (215)

Forest plot showing changes in Cardiac troponin-I of the Mavacamten group compared to placebo at random effect.

Forest plot showing changes in Cardiac troponin-I of the Mavacamten group compared to placebo at random effect.
Kalgi Modi (7699319), Mansunderbir Singh (18405132), Anuj Thakre (18405138), Sahith Reddy Thotamgari (15947040), Rahul Vyas (18405123), Shubhika Jain (17719146), Viraj Panchal (18405126), Keerthish Jaisingh (18405135), Manush Sondhi (18405129)   +8 more
core   +1 more source

Mavacamten in Symptomatic Patients Resistant to Previous Advanced Therapy for Obstructive Hypertrophic Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background The clinical benefits of mavacamten in patients with obstructive hypertrophic cardiomyopathy previously treated with advanced therapies are not established.
Daniele Massera, Elizabeth Adlestein, Sumar Frejat, Woon Y. Wu, Maria C. Reuter, Yuhe Xia, Isabel C. Alvarez, Mark V. Sherrid   +7 more
doaj   +1 more source

Comparison of alcohol septal ablation and mavacamten in patients with obstructive hypertrophic cardiomyopathy: a propensity-matched large single-center study

Background: Obstructive hypertrophic cardiomyopathy (oHCM) causes substantial symptom burden and impaired functional capacity. Mavacamten has emerged as a targeted pharmacologic treatment, whereas alcohol septal ablation (ASA) is an established septal ...
Christoph Reich, Jan Koelemen, Kay Becht, Ali Amr, Farbod Sedaghat-Hamedani, Benjamin Meder, Steffen Rosskopf, Elham Kayvanpour, Norbert Frey   +8 more
core   +1 more source

Advancements in the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Comprehensive Review

Journal of Cardiovascular Development and Disease
Hypertrophic cardiomyopathy (HCM) is characterized by excessive growth of myocardial tissue, most commonly due to genetic mutations in sarcomere proteins.
Randeep Gill, Arsalan Siddiqui, Brianna Yee, Michael V. DiCaro, Nazanin Houshmand, Tahir Tak   +5 more
doaj   +1 more source

Recent Advances in Novel Modulators for Cardiac Myosin Disorders

Pharmaceutical Fronts
In advanced stages of heart disease, most cases are characterized by heart failure, where the heart's systolic and diastolic functions are weakened, and then it cannot meet the body's normal oxygen demands.
Hancheng Wang, Mengfei Wang, Bo Han, Qiushi Chen, Qingwei Zhang   +4 more
doaj   +1 more source

Catastrophic apical ballooning in an obstructive hypertrophic cardiomyopathy patient treated with mavacamten: case report

European Heart Journal: Case Reports
Background Obstructive hypertrophic cardiomyopathy (oHCM) is a complex condition characterized by left ventricular outflow tract obstruction (LVOTO) in the setting of a hypercontractile and hypertrophic left ventricle.
F. De Roeck, Frederik Lahaye, A. Gevaert, R. De Paep, E. Van Craenenbroeck   +4 more
semanticscholar   +1 more source

Forest plot showing changes in LVOT at post-exercise of Mavacamten compared to placebo at random effect.

Forest plot showing changes in LVOT at post-exercise of Mavacamten compared to placebo at random effect.
Kalgi Modi (7699319), Mansunderbir Singh (18405132), Anuj Thakre (18405138), Sahith Reddy Thotamgari (15947040), Rahul Vyas (18405123), Shubhika Jain (17719146), Viraj Panchal (18405126), Keerthish Jaisingh (18405135), Manush Sondhi (18405129)   +8 more
core   +1 more source

Forest plot showing changes in LVOT at rest of the Mavacamten group compared to placebo at random effect.

Forest plot showing changes in LVOT at rest of the Mavacamten group compared to placebo at random effect.
Kalgi Modi (7699319), Mansunderbir Singh (18405132), Anuj Thakre (18405138), Sahith Reddy Thotamgari (15947040), Rahul Vyas (18405123), Shubhika Jain (17719146), Viraj Panchal (18405126), Keerthish Jaisingh (18405135), Manush Sondhi (18405129)   +8 more
core   +1 more source

Forest plot showing changes in LVOT at post-valsalva of the Mavacamten group compared to placebo at random effect.

Forest plot showing changes in LVOT at post-valsalva of the Mavacamten group compared to placebo at random effect.
Kalgi Modi (7699319), Mansunderbir Singh (18405132), Anuj Thakre (18405138), Sahith Reddy Thotamgari (15947040), Rahul Vyas (18405123), Shubhika Jain (17719146), Viraj Panchal (18405126), Keerthish Jaisingh (18405135), Manush Sondhi (18405129)   +8 more
core   +1 more source

Myosin folding boosts solubility in cardiac muscle sarcomeres

JCI Insight
The polymerization of myosin molecules into thick filaments in muscle sarcomeres is essential for cardiac contractility, with the attenuation of interactions between the heads of myosin molecules within the filaments being proposed to result in ...
Colleen M. Kelly, Jody L. Martin, Michael J. Previs   +2 more
doaj   +1 more source